NASDAQ · Biotechnology

XFOR (XFOR) Stock

$4.29 +4.89% NASDAQ: XFOR Healthcare

Valuation

MetricValue
Price$4.29
Market Cap$404.63M
P/E Ratio-1.96
P/B Ratio0.22
P/S Ratio4.72
EPS (TTM)$-1.87
52-Week High$4.83
52-Week Low$1.35
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.47%
ROA-27.24%
ROCE-46.77%
Gross Margin-248.57%
Operating Margin-248.57%
Net Margin-11.06%
Debt/Equity0.41
Current Ratio10.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$35.0M
Operating Profit$-75.0M$-88.0M$-108.0M$-36.0M$-87.0M
Net Profit$-89.0M$-94.0M$-101.0M$-37.0M$-79.0M
EPS$-119.58$-45.60$-17.07$-5.59$-1.87
Op Margin———-1423.6%-247.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$117.0M$156.0M$147.0M$146.0M$290.0M
Total Liabilities$53.0M$82.0M$96.0M$124.0M$104.0M
Cash$82.0M$122.0M$99.0M$56.0M$217.0M
Borrowings$40.0M$38.0M$58.0M$78.0M$77.0M

Latest News

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 7, 2026 X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors GlobeNewswire · Jul 1, 2026 X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 27, 2026 How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress Simply Wall St. · May 21, 2026 Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now Zacks · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-71.0M$-77.0M$-97.0M$-131.0M$-86.0M
Investing Cash Flow$-1.0M$0$-15.0M$60.0M$5.0M
Financing Cash Flow$-2.0M$-5.0M$8.0M$0$0
Net Cash Flow$3.0M$40.0M$-23.0M$-44.0M$161.0M
Free Cash Flow$-72.0M$-77.0M$-97.0M$-138.0M$-89.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-172.14%
Quick Ratio9.98
Interest Coverage-9.67
Return 1Y166.00%
Return 3Y-92.44%
Return 5Y-97.67%

Ownership

Insiders Held0.54%
Institutions Held100.42%
Institutions Float Held100.96%
Institutional HolderSharesReport Date
Morgan Stanley9,466,9922026-03-31
Empery Asset Management, LP8,944,1182026-03-31
FMR, LLC8,103,4002026-03-31
Bain Capital Life Sciences Investors, LLC7,967,4542026-03-31
Perceptive Advisors Llc6,737,6482026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
KPTIKaryopharm Therapeutics Inc. $7.60 +2.56% -0.50 $172.24M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About XFOR

XFOR is led by CEO Adam R. Craig, employs 143 people, headquartered in US, publicly traded since 2017.

XFOR stock trades at $4.29 with a market capitalization of $404.63M. The stock is valued at a price-to-earnings (P/E) ratio of -1.96, price-to-book of 0.22, price-to-sales of 4.72. Over the past 52 weeks the stock has ranged between $1.35 and $4.83, and currently trades 11.2% below its 52-week high.

On profitability, XFOR generates a return on equity (ROE) of -42.47%, return on capital employed of -46.77%, an operating margin of -248.57%, a net profit margin of -11.06%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides